As millions of people begin long-term GLP-1 therapy, we are facing a potential public health shift toward "thin-obese" phenotypes. This episode dives into the clinical data regarding muscle-to-fat loss ratios and discusses why healthcare providers must pivot from simple caloric restriction to a muscle-centric medical model. We examine the long-term metabolic implications of muscle loss and what it means for the future of aging in the GLP-1 era.